GeneralConnection.com ➔ Dictionary
Dictionary Search

factor ix

Synonyms

Noun

1. Christmas factor

2. factor IX, coagulation factor, clotting factor

Usage
Pfizer receives EC approval for Hympavzi to treat haemophilia - Yahoo
Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B - Docwire News
Advances in hemophilia, sickle cell disease, and thalassemia - Penn Medicine
Karmanos Cancer Institute Becomes First and Only Free-Standing Cancer Center to Treat Hemophilia B with New Gene Therapy - McLaren Health
EAHAD 2026: Nine-Year Outcomes of Gene Therapy - EMJ
Hemophilia B Gene Therapy Continues to Reduce Bleeding - Medscape
Gene Therapy Supply Runs Out, Company Warns of Treatment Delays - MedPage Today
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Explainer: Why Is Hemophilia B Called Christmas Disease? - Global Biotechnology Company
Optimization of hemophilia B treatment via population PK modeling of rIX-FP, including a 3-week regimen - Frontiers
ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years - Fierce Pharma
Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting - Biogen
The National “New Methods” Decision Forum in Norway recommends CSL’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B without a history of Factor IX inhibitors - Mynewsdesk
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years - MedPage Today
This gene therapy costs $5 million a dose. Is it worth the price? - SMH.com.au
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties - Nature
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years - Mynewsdesk
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant - The New England Journal of Medicine
How Gene Therapy Is Transforming Hemophilia B Treatment - Docwire News
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - The New England Journal of Medicine
Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product - Nature
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B - The New England Journal of Medicine
How durable is gene therapy for haemophilia B? - Nature
Systemic delivery of factor IX messenger RNA for protein replacement therapy - PNAS
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies - Nature
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) - The New England Journal of Medicine
TestroVax Growth Factor-9 Stack for Penis and Performance Support - Portal CNJ
Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence - Nature
Vitamin K-dependent carboxylation of coagulation factors: insights from a cell-based functional study - Haematologica
Plasma factor IX: The tip of the iceberg? - Sidonio - 2021 - Haemophilia - Wiley Online Library
A novel snake venom C-type lectin-like protein modulates blood coagulation by targeting von Willebrand factor and coagulation factor IX - Nature
New Recombinant Factor IX Leads to Significant Cost Savings in Hemophilia B - AJMC
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX - American Heart Association Journals
Etranacogene Dezaparvovec Displays Superiority to Factor IX Prophylaxis for Hemophilia B in HOPE-B Trial Data - CGTLive®
Field Study Highlights Differences in Factor IX Variant Lab Results - AJMC
First gene therapy to treat haemophilia B - European Medicines Agency (EMA)
HTC Population Profile Patient Characteristics - Centers for Disease Control and Prevention | CDC (.gov)
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space - Wiley
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab - American Heart Association Journals
First subject dosed in Be Biopharma’s trial of haemophilia B therapy - Clinical Trials Arena
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
CDC Hemophilia Mutation Projects (CHAMP and CHBMP) - Centers for Disease Control and Prevention | CDC (.gov)
Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis - American Heart Association Journals
A coagulation factor moonlights in the heart - Science | AAAS
Factor IX Deficiency and Prolonged Bleeding Time - The New England Journal of Medicine
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Wiley Online Library
Hemophilia B Durham: A Mutation in the First EGF-Like Domain of Factor IX That Is Characterized by Polymerase Chain Reaction - ScienceDirect.com
Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI - PNAS
Association Between Hepatic Triglyceride Content and Coagulation Factors: - American Heart Association Journals
Factor Levels Lower Than 50% Associated With Postpartum Complications in Patients With Hemophilia - Hematology Advisor
Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B - 2 Minute Medicine
UC San Diego Health First to Offer Novel Gene Therapy for Hemophilia B - UC San Diego Health
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial - Applied Clinical Trials Online
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B - Biogen
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A - The New England Journal of Medicine
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - The New England Journal of Medicine
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors - Nature
One dose of gene therapy gives years of relief from blood disorder - Nature
Gene therapy fails to induce sustained factor IX activity for patients with hemophilia B - Healio
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
Intellia opts out of hemophilia B gene editing work with Regeneron - Fierce Biotech
St. Jude's contribution to two new durable 'one-time' hemophilia drugs - St. Jude Children's Research Hospital
Pfizer: Beqvez Gene Therapy Decreases Bleeding Rates in Hemophilia B Patients - 2 Minute Medicine
Glucocorticoids increase adiposity by stimulating Krüppel-like factor 9 expression in macrophages - Nature
Krüppel-like factor 9 alleviates Alzheimer’s disease via IDE-mediated Aβ degradation - Nature
Hemophilia B Gene Therapy Shows Promise as Long-Term Treatment - Docwire News
Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B - 2 Minute Medicine
Evaluation of a New Concentrate for the Treatment of Factor IX Deficiency - The New England Journal of Medicine
Hemophilia B Gene Therapy Produces Durable Response for 90% of Participants - AJMC
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response - Nature
Hemophilia B Gene Therapy Sustains Efficacy Over a Decade Later - MedPage Today
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis - MedPage Today
Personal Story: Carrie - Centers for Disease Control and Prevention | CDC (.gov)
Pulmonary Hemorrhage: An Unusual Life-Threatening Presentation of Factor IX Deficiency in a Monochorionic-Diamniotic Twin Neonate - Cureus
Gene Therapy Cuts Bleeding and Medicine for Hemophilia B Patients for Over a Decade - Managed Healthcare Executive
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector - Nature
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X - PNAS
Emicizumab Prophylaxis in Hemophilia A with Inhibitors - The New England Journal of Medicine
Effective Blood Clotting Treatment:Pharmacogenomic Studies of ADAMTS13 - fda.gov
Is Hemophilia a Nosologic Entity? - ScienceDirect.com
Hemophilia Gene Therapies Show Effectiveness and Safety in NEJM Reports - Inside Precision Medicine
A genetic analysis of 23 Chinese patients with hemophilia B - Nature
Interferon Regulatory Factor 9 Structure and Regulation - Frontiers
Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma - Nature
Single-dose gene therapy is potentially life-changing for adults with hemophilia B - Penn Medicine
Hemophilia therapy: the future has begun - Haematologica
Factor IX product launched in US - MDEdge
FDA Approves Second Gene Therapy for Hemophilia B - Medscape
Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond - The Lancet
Hemophilia B Gene Therapy Shows Promise in Clinical Trial - Genetic Engineering and Biotechnology News
Researchers welcome $3.5-million haemophilia gene therapy — but questions remain - Nature
uniQure announces FDA approval of first gene therapy for adults with hemophilia B - uniqure.gcs-web.com
New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use - Biogen
Long-term phenotypic correction in factor IX knockout mice by using phiC31 integrase-mediated gene therapy - Nature
The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A - The New England Journal of Medicine
Loss of Krüppel-like factor 9 deregulates both physiological gene expression and development - Nature
Foreign Language Equivalents
Foreign Language Equivalents of 'factor ix'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
factor ic,   facyor ix,   factro ix,   favtor ix,   factor ux,   factorr ix,   fctor ix,   factir ix,   faxtor ix,   factor ixx,   factot ix,   facto rix,   fatcor ix,   factor iz,   factor iix,   faactor ix,   factpr ix,   factor ox,   afctor ix,   gactor ix,   facotr ix,   fsctor ix,   factor i,   facor ix,   factor ix,   facror ix,   factorix,   facto ix,   factor x,   fcator ix,   factor xi,   facttor ix,   dactor ix,   factr ix,   fator ix,   factori x,   facter ix,   factoe ix,   actor ix,   ffactor ix,   factoor ix,   facctor ix
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z